Beauty Health Analyst Ratings
Beauty Health Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/14/2023 | 96.08% | Stifel | $8 → $3 | Maintains | Hold |
11/14/2023 | — | Benchmark | Downgrades | Buy → Hold | |
11/14/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
11/14/2023 | 63.4% | TD Cowen | $9 → $2.5 | Downgrades | Outperform → Market Perform |
11/14/2023 | — | Raymond James | Downgrades | Market Perform → Underperform | |
11/14/2023 | 30.72% | Piper Sandler | $12 → $2 | Downgrades | Overweight → Underweight |
11/14/2023 | 63.4% | Canaccord Genuity | $10 → $2.5 | Downgrades | Buy → Hold |
11/14/2023 | — | JP Morgan | Downgrades | Neutral → Underweight | |
09/13/2023 | 1403.27% | Benchmark | → $23 | Reiterates | Buy → Buy |
08/25/2023 | 553.59% | Canaccord Genuity | → $10 | Assumes | → Buy |
08/10/2023 | 488.24% | TD Cowen | $15 → $9 | Maintains | Outperform |
08/10/2023 | 978.43% | DA Davidson | $35 → $16.5 | Maintains | Buy |
08/08/2023 | 1403.27% | Benchmark | → $23 | Reiterates | Buy → Buy |
06/21/2023 | 553.59% | Stifel | $17 → $10 | Downgrades | Buy → Hold |
05/26/2023 | 684.31% | JP Morgan | $13 → $12 | Maintains | Neutral |
05/18/2023 | 1403.27% | Benchmark | → $23 | Reiterates | Buy → Buy |
05/11/2023 | 2187.58% | DA Davidson | → $35 | Reiterates | → Buy |
03/28/2023 | 1076.47% | Canaccord Genuity | → $18 | Reiterates | → Buy |
03/20/2023 | — | Exane BNP Paribas | Upgrades | Underperform → Neutral | |
03/14/2023 | 1403.27% | Benchmark | → $23 | Reiterates | → Buy |
03/01/2023 | 2187.58% | DA Davidson | $32 → $35 | Maintains | Buy |
02/28/2023 | 1403.27% | Benchmark | → $23 | Reiterates | → Buy |
02/16/2023 | 880.39% | Cowen & Co. | $20 → $15 | Maintains | Outperform |
11/23/2022 | 1141.83% | Goldman Sachs | $22 → $19 | Maintains | Buy |
11/09/2022 | 618.95% | JP Morgan | $22 → $11 | Downgrades | Overweight → Neutral |
11/09/2022 | 1991.5% | DA Davidson | $31 → $32 | Maintains | Buy |
09/28/2022 | 1926.14% | DA Davidson | $30 → $31 | Maintains | Buy |
09/16/2022 | 1403.27% | Piper Sandler | $20 → $23 | Maintains | Overweight |
09/16/2022 | 1860.78% | DA Davidson | $25 → $30 | Maintains | Buy |
08/16/2022 | 1337.91% | Goldman Sachs | $25 → $22 | Maintains | Buy |
08/10/2022 | 1207.19% | Piper Sandler | $22 → $20 | Maintains | Overweight |
08/10/2022 | 1533.99% | DA Davidson | $24 → $25 | Maintains | Buy |
07/08/2022 | 1337.91% | Piper Sandler | $24 → $22 | Maintains | Overweight |
06/30/2022 | 1207.19% | Canaccord Genuity | $22 → $20 | Maintains | Buy |
05/12/2022 | 1468.63% | DA Davidson | $35 → $24 | Maintains | Buy |
05/11/2022 | 1533.99% | Goldman Sachs | $29 → $25 | Maintains | Buy |
05/11/2022 | 1468.63% | Piper Sandler | $26 → $24 | Maintains | Overweight |
04/28/2022 | 1599.35% | Piper Sandler | $31 → $26 | Maintains | Overweight |
03/14/2022 | 1403.27% | Benchmark | $18 → $23 | Maintains | Buy |
03/11/2022 | 1468.63% | JP Morgan | → $24 | Initiates Coverage On | → Overweight |
02/23/2022 | 2187.58% | DA Davidson | $32 → $35 | Maintains | Buy |
01/07/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
12/23/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
11/10/2021 | 1991.5% | DA Davidson | $26 → $32 | Maintains | Buy |
10/08/2021 | 2056.86% | Stifel | → $33 | Initiates Coverage On | → Buy |
10/04/2021 | 1991.5% | Cowen & Co. | → $32 | Initiates Coverage On | → Outperform |
08/11/2021 | 1599.35% | DA Davidson | $17.5 → $26 | Maintains | Buy |
07/19/2021 | 1337.91% | Jefferies | → $22 | Initiates Coverage On | → Buy |
07/01/2021 | 1926.14% | Goldman Sachs | → $31 | Initiates Coverage On | → Buy |
06/24/2021 | 1468.63% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
06/15/2021 | 1272.55% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
06/01/2021 | 1043.79% | DA Davidson | $16 → $17.5 | Maintains | Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/14/2023 | 96.08% | Stifel | 8 美元 → 3 美元 | 维护 | 保持 |
11/14/2023 | — | 基准 | 降级 | 买入 → 持有 | |
11/14/2023 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
11/14/2023 | 63.4% | TD Cowen | 9 美元 → 2.5 美元 | 降级 | 跑赢大盘 → 市场表现 |
11/14/2023 | — | 雷蒙德·詹姆 | 降级 | 市场表现 → 跑赢大盘 | |
11/14/2023 | 30.72% | 派珀·桑德勒 | 12 美元 → 2 美元 | 降级 | 超重 → 体重不足 |
11/14/2023 | 63.4% | Canaccord Genu | 10 美元 → 2.5 美元 | 降级 | 买入 → 持有 |
11/14/2023 | — | 摩根大通 | 降级 | 中性 → 体重不足 | |
09/13/2023 | 1403.27% | 基准 | → 23 美元 | 重申 | 购买 → 购买 |
08/25/2023 | 553.59% | Canaccord Genu | → 10 美元 | 假设 | → 购买 |
08/10/2023 | 488.24% | TD Cowen | 15 美元 → 9 美元 | 维护 | 跑赢大盘 |
08/10/2023 | 978.43% | DA Davidson | 35 美元 → 16.5 美元 | 维护 | 买 |
08/08/2023 | 1403.27% | 基准 | → 23 美元 | 重申 | 购买 → 购买 |
06/21/2023 | 553.59% | Stifel | 17 美元 → 10 美元 | 降级 | 买入 → 持有 |
05/26/2023 | 684.31% | 摩根大通 | 13 美元 → 12 美元 | 维护 | 中立 |
05/18/2023 | 1403.27% | 基准 | → 23 美元 | 重申 | 购买 → 购买 |
05/11/2023 | 2187.58% | DA Davidson | → 35 美元 | 重申 | → 购买 |
03/28/2023 | 1076.47% | Canaccord Genu | → 18 美元 | 重申 | → 购买 |
03/20/2023 | — | Exane BNP Paribas | 升级 | 表现不佳 → 中性 | |
03/14/2023 | 1403.27% | 基准 | → 23 美元 | 重申 | → 购买 |
03/01/2023 | 2187.58% | DA Davidson | 32 美元 → 35 美元 | 维护 | 买 |
02/28/2023 | 1403.27% | 基准 | → 23 美元 | 重申 | → 购买 |
02/16/2023 | 880.39% | Cowen & Co. | 20 美元 → 15 美元 | 维护 | 跑赢大盘 |
2022 年 11 月 23 日 | 1141.83% | 高盛 | 22 美元 → 19 美元 | 维护 | 买 |
11/09/2022 | 618.95% | 摩根大通 | 22 美元 → 11 美元 | 降级 | 超重 → 中性 |
11/09/2022 | 1991.5% | DA Davidson | 31 美元 → 32 美元 | 维护 | 买 |
2022 年 9 月 28 日 | 1926.14% | DA Davidson | 30 美元 → 31 美元 | 维护 | 买 |
2022 年 9 月 16 日 | 1403.27% | 派珀·桑德勒 | 20 美元 → 23 美元 | 维护 | 超重 |
2022 年 9 月 16 日 | 1860.78% | DA Davidson | 25 美元 → 30 美元 | 维护 | 买 |
08/16/2022 | 1337.91% | 高盛 | 25 美元 → 22 美元 | 维护 | 买 |
08/10/2022 | 1207.19% | 派珀·桑德勒 | 22 美元 → 20 美元 | 维护 | 超重 |
08/10/2022 | 1533.99% | DA Davidson | 24 美元 → 25 美元 | 维护 | 买 |
07/08/2022 | 1337.91% | 派珀·桑德勒 | 24 美元 → 22 美元 | 维护 | 超重 |
06/30/2022 | 1207.19% | Canaccord Genu | 22 美元 → 20 美元 | 维护 | 买 |
05/12/2022 | 1468.63% | DA Davidson | 35 美元 → 24 美元 | 维护 | 买 |
05/11/2022 | 1533.99% | 高盛 | 29 美元 → 25 美元 | 维护 | 买 |
05/11/2022 | 1468.63% | 派珀·桑德勒 | 26 美元 → 24 美元 | 维护 | 超重 |
04/28/2022 | 1599.35% | 派珀·桑德勒 | 31 美元 → 26 美元 | 维护 | 超重 |
03/14/2022 | 1403.27% | 基准 | 18 美元 → 23 美元 | 维护 | 买 |
03/11/2022 | 1468.63% | 摩根大通 | → 24 美元 | 启动覆盖范围开启 | → 超重 |
2022 年 2 月 23 日 | 2187.58% | DA Davidson | 32 美元 → 35 美元 | 维护 | 买 |
2022 年 7 月 1 日 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
12/23/2021 | — | 雷蒙德·詹姆 | 启动覆盖范围开启 | → 市场表现 | |
11/10/2021 | 1991.5% | DA Davidson | 26 美元 → 32 美元 | 维护 | 买 |
2021 年 8 月 10 日 | 2056.86% | Stifel | → 33 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 4 月 10 日 | 1991.5% | Cowen & Co. | → 32 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
08/11/2021 | 1599.35% | DA Davidson | 17.5 美元 → 26 美元 | 维护 | 买 |
07/19/2021 | 1337.91% | 杰富瑞集团 | → 22 美元 | 启动覆盖范围开启 | → 购买 |
07/01/2021 | 1926.14% | 高盛 | → 31 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 6 月 24 日 | 1468.63% | 派珀·桑德勒 | → 24 美元 | 启动覆盖范围开启 | → 超重 |
06/15/2021 | 1272.55% | Canaccord Genu | → 21 美元 | 启动覆盖范围开启 | → 购买 |
06/01/2021 | 1043.79% | DA Davidson | 16 美元 → 17.5 美元 | 维护 | 买 |
What is the target price for Beauty Health (SKIN)?
Beauty Health(SKIN)的目标价格是多少?
The latest price target for Beauty Health (NASDAQ: SKIN) was reported by Stifel on November 14, 2023. The analyst firm set a price target for $3.00 expecting SKIN to rise to within 12 months (a possible 96.08% upside). 24 analyst firms have reported ratings in the last year.
Stifel于2023年11月14日公布了美容健康(纳斯达克股票代码:SKIN)的最新目标股价。该分析公司将目标股价定为3.00美元,预计SKIN将在12个月内升至12个月内(可能上涨96.08%)。去年有24家分析公司公布了评级。
What is the most recent analyst rating for Beauty Health (SKIN)?
分析师对美容健康(SKIN)的最新评级是多少?
The latest analyst rating for Beauty Health (NASDAQ: SKIN) was provided by Stifel, and Beauty Health maintained their hold rating.
Stifel提供了Beauty Health(纳斯达克股票代码:SKIN)的最新分析师评级,Beauty Health维持其持有评级。
When is the next analyst rating going to be posted or updated for Beauty Health (SKIN)?
Beauty Health(SKIN)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beauty Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beauty Health was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Beauty Health的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。美容健康的最新评级是在2023年11月14日发布的,因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Beauty Health (SKIN) correct?
分析师对美容健康 (SKIN) 的评级是否正确?
While ratings are subjective and will change, the latest Beauty Health (SKIN) rating was a maintained with a price target of $8.00 to $3.00. The current price Beauty Health (SKIN) is trading at is $1.53, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的美容健康(SKIN)评级保持不变,目标价为8.00美元至3.00美元。Beauty Health(SKIN)目前的交易价格为1.53美元,超出了分析师的预期区间。